Roche Holding AG (RHHBF)
| Market Cap | 341.10B +32.7% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 22.33 |
| Forward PE | 16.46 |
| Dividend | 12.41 (2.98%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | n/a |
| Open | 430.00 |
| Previous Close | 425.19 |
| Day's Range | 430.00 - 430.00 |
| 52-Week Range | 296.10 - 514.08 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche Cuts Generic Sales Hit to $736 Million, Shares Jump 3.2%
Roche Cuts Generic Sales Hit to $736 Million, Shares Jump 3.2%
Roche Holding AG Earnings Call Transcript: H1 2026
Core operating profit grew 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high, with five FDA priority reviews, major launches, and robust cash flow, supporting a positive outlook despite currency and competitive headwinds.
Roche Holding AG Quarterly report: H1 2026
Roche Holding AG has published its H1 2026 quarterly earnings report on July 23, 2026.
Roche Holding AG Slides: H1 2026
Roche Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 23, 2026.
Roche Holding AG Earnings release: H1 2026
Roche Holding AG released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche's GLP-1 drug showing stronger weight loss than rival, says CEO
Thomas Schinecker, CEO of Roche, discusses U.S. pharmaceutical tariffs, the company's product pipeline, global manufacturing, and the impact of AI on the business.
Roche Holding (RHHBY) Reports Strong 1H Results with Growth in Pharmaceuticals Division
Roche Holding (RHHBY) Reports Strong 1H Results with Growth in Pharmaceuticals Division
Roche H1 Profit Drops On Lower Revenues
(RTTNews) - Swiss healthcare major Roche Holding AG (RHHBY, RO.SW) reported Thursday lower profit in its first half with weak revenues.
Roche Backs Full-Year View as First-Half Sales Rise
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation seque...
MaxCyte Signs Multi-Platform Technology License Partnership With Genentech
(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a multi-platform technology license partnership with Genentech, a member of the Roche Group (RHHBY), to advance the development of next-generation cel...
Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) ...
MaxCyte enters technology license partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides…
Roche Appoints Dan Malarek CEO Of Diagnostics North America; Names U.S. Commercial Chief
(RTTNews) - Roche Holding AG (RO.SW) announced the appointment of Dan Malarek as President and Chief Executive Officer of Roche Diagnostics North America, effective August 1, 2026. He succeeds Brad Mo...
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
Roche (RHHBY) announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1. Malarek currently serves as Chief Executive Officer of Foundation Me...
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America
Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end o...
Roche (RHHBY) Receives FDA Priority Review for Gazyva Kidney Therapy Expansion
Roche (RHHBY) Receives FDA Priority Review for Gazyva Kidney Therapy Expansion
Genentech granted priority review for Gazyva sBLA by FDA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted priority review to the company’s supplemental biologics license application, or sBLA, for Gazyva for the treatment of primary…
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Appl...
FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has grant...
Roche Introduces First Fully Automated Hepatitis D Virus Test
(RTTNews) - Roche (RHHBY) has launched the cobas Hepatitis D Virus test, the first fully automated diagnostic solution to detect and quantify HDV RNA. The assay runs on Roche's cobas 5800/6800/8800 sy...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Basel, 14 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and qu...
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials
Ionis Pharmaceuticals (IONS) Shares Drop After Roche Discontinues Trials